{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:53:45Z","timestamp":1781049225672,"version":"3.54.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":389,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Scientific Research Program of Tianjin Municipal Education Commission","award":["2021KJ229"],"award-info":[{"award-number":["2021KJ229"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure (HF) is a leading cause of mortality in patients with end-stage renal disease (ESRD) undergoing haemodialysis. Identifying novel predictors of HF is essential for improving diagnostic precision and enhancing patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 68 participants from the Haemodialysis Centre at the Second Hospital of Tianjin Medical University. Clinical characteristics and echocardiographic data were collected and analysed. We measured the plasma of 44 cytokines to investigate their correlation with cardiac function and their potential as HF biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the HF with reduced ejection fraction (HFrEF) group, the levels of several cytokines, including stem cell growth factor-\u03b2 (SCGF-\u03b2), C\u2013X\u2013C motif chemokine 10 (CXCL10), interleukin-1\u03b1 (IL-1\u03b1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-16 (IL-16), interleukin-1 receptor antagonist protein (IL-1Ra), interferon-\u03b3 (IFN-\u03b3), tumour necrosis factor-\u03b1 (TNF-\u03b1), leukaemia inhibitory factor (LIF), C\u2013C motif chemokine 3 (CCL3), interleukin-10 (IL-10), interleukin-2 receptor subunit alpha (IL-2R\u03b1), tumour necrosis factor ligand superfamily member 10 (TNFSF10), macrophage colony-stimulating factor (M-CSF), granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF), were significantly increased, while C\u2013C motif chemokine 11 (CCL11)\/eotaxin levels were decreased compared with those in the control group (P &amp;lt; 0.05). Receiver operating characteristic (ROC) curve analysis highlighted TNF-\u03b1 [area under the ROC curve (AUC) = 0.85, odds ratio (OR) = 1.080, 95% confidence interval (CI): 1.033\u20131.128, P = 0.001], IFN-\u03b3 (AUC = 0.84, OR = 1.836, 95% CI: 1.289\u20132.615, P = 0.003) and IL-2R\u03b1 (AUC = 0.82, OR = 1.022, 95% CI: 1.009\u20131.035, P = 0.001) as excellent predictors for HFrEF in haemodialysis patients with ESRD, and they outperformed soluble suppression of tumourigenicity-2 (sST2) but slightly underperformed N-terminal pro-brain natriuretic peptide (NT-proBNP). IL-2R\u03b1 (AUC = 0.77, OR = 1.018, 95% CI: 1.007\u20131.030, P = 0.001) demonstrated superior diagnostic capabilities when distinguishing patients with HF with left ventricular ejection fraction (LVEF) &amp;lt;50% from controls. IL-2R\u03b1 emerged as a robust biomarker for left ventricular HF, while TNF-\u03b1 (AUC = 0.89, OR = 1.140, 95% CI: 1.039\u20131.250, P = 0.005) showed promise in assessing HF severity in patients with ESRD. IL-2R\u03b1 (AUC = 0.80, OR = 1.017, 95% CI: 1.007\u20131.027, P = 0.001) also significantly predicted right ventricular systolic dysfunction. During a median follow-up of 14 months, 10 patients (14.7%) experienced all-cause mortality. Multivariate Cox regression analysis confirmed that plasma IL-2R\u03b1 was an independent predictor of all-cause death [hazard ratio (HR): 1.010, 95% CI: 1.001\u20131.020, P = 0.039] after adjusting for other variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study underscores the potential of IL-2R\u03b1 as a valuable biomarker for HF diagnosis and management in haemodialysis patients with ESRD and contributes to our understanding of this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15051","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T08:03:52Z","timestamp":1726128232000},"page":"118-132","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["IL-2R\u03b1 is a Potential Biomarker for Heart Failure Diagnosis of Patients with End-Stage Renal Disease and Haemodialysis"],"prefix":"10.1093","volume":"12","author":[{"given":"Bingya","family":"Lv","sequence":"first","affiliation":[{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , Tianjin ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Kidney Disease and Blood Purification Centre, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , Tianjin ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Suo","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , Tianjin ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Shao","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , Tianjin ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Yuan","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , Tianjin ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , Tianjin ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Kidney Disease and Blood Purification Centre, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , Tianjin ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangping","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , Tianjin ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5221-2780","authenticated-orcid":false,"given":"Qiankun","family":"Bao","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , Tianjin ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"2026012113063080000_ehf215051-bib-0001","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"2026012113063080000_ehf215051-bib-0002","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2215\/CJN.00730805","article-title":"Kidney-heart interactions: Epidemiology, pathogenesis, and treatment","volume":"1","author":"Berl","year":"2006","journal-title":"Clin J Am Soc Nephrol: CJASN"},{"key":"2026012113063080000_ehf215051-bib-0003","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1523-1755.2005.00397.x","article-title":"Chronic kidney disease and cardiovascular disease in a general Japanese population: The Hisayama Study","volume":"68","author":"Ninomiya","year":"2005","journal-title":"Kidney Int"},{"key":"2026012113063080000_ehf215051-bib-0004","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/eurjhf\/hfr176","article-title":"Right ventricular dysfunction is associated with chronic kidney disease and predicts survival in patients with chronic systolic heart failure","volume":"14","author":"Dini","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026012113063080000_ehf215051-bib-0005","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrneph.2013.44","article-title":"Immune cell dysfunction and inflammation in end-stage renal disease","volume":"9","author":"Betjes","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2026012113063080000_ehf215051-bib-0006","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000479254","article-title":"End-stage renal disease, inflammation and cardiovascular outcomes","volume":"191","author":"Dai","year":"2017","journal-title":"Contrib Nephrol"},{"key":"2026012113063080000_ehf215051-bib-0007","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.cca.2020.07.040","article-title":"Cardiac biomarkers of heart failure in chronic kidney disease","volume":"510","author":"Han","year":"2020","journal-title":"Clin Chim Acta"},{"key":"2026012113063080000_ehf215051-bib-0008","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/pgmj.2008.073734","article-title":"Natriuretic peptides and heart failure in the patient with chronic kidney disease: A review of current evidence","volume":"85","author":"Dhar","year":"2009","journal-title":"Postgrad Med J"},{"key":"2026012113063080000_ehf215051-bib-0009","doi-asserted-by":"crossref","first-page":"59b","DOI":"10.1016\/j.amjcard.2015.01.042","article-title":"Structural heart disease and ST2: Cross-sectional and longitudinal associations with echocardiography","volume":"115","author":"deFilippi","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026012113063080000_ehf215051-bib-0010","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ekir.2018.09.013","article-title":"Soluble ST2 and galectin-3 and progression of CKD","volume":"4","author":"Alam","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2026012113063080000_ehf215051-bib-0011","doi-asserted-by":"publisher","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of biomarkers for the prevention, assessment, and management of heart failure: A scientific statement from the American Heart Association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"},{"key":"2026012113063080000_ehf215051-bib-0012","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/CIR.0000000000001062","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026012113063080000_ehf215051-bib-0013","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000496064","article-title":"Grading of left ventricular diastolic dysfunction with preserved systolic function by the 2016 American Society of Echocardiography\/European Association of Cardiovascular Imaging recommendations contributes to predicting cardiovascular events in hemodialysis patients","volume":"9","author":"Toida","year":"2019","journal-title":"Cardiorenal Med"},{"key":"2026012113063080000_ehf215051-bib-0014","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12947-020-00217-y","article-title":"Quantification of left ventricular mass by echocardiography compared to cardiac magnet resonance imaging in hemodialysis patients","volume":"18","author":"Grebe","year":"2020","journal-title":"Cardiovasc Ultrasound"},{"key":"2026012113063080000_ehf215051-bib-0015","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver operating characteristic curve in diagnostic test assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J Thorac oncol"},{"key":"2026012113063080000_ehf215051-bib-0016","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/ehf2.14289","article-title":"Prognostic implication of a novel right ventricular injury score in septic patients","volume":"10","author":"Zhang","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026012113063080000_ehf215051-bib-0017","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12186105","article-title":"Heart failure in patients with chronic kidney disease","volume":"12","author":"Xanthopoulos","year":"2023","journal-title":"J Clin Med"},{"key":"2026012113063080000_ehf215051-bib-0018","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.pcad.2016.12.003","article-title":"The cardio-renal interrelationship","volume":"59","author":"Boudoulas","year":"2017","journal-title":"Prog Cardiovasc Dis"},{"key":"2026012113063080000_ehf215051-bib-0019","doi-asserted-by":"publisher","first-page":"iii35","DOI":"10.1093\/ndt\/gfy175","article-title":"Chronic inflammation in end-stage renal disease and dialysis","volume":"33","author":"Cobo","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2026012113063080000_ehf215051-bib-0020","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1525-139X.2010.00784.x","article-title":"Inflammation in end-stage renal disease\u2014What have we learned in 10 years?","volume":"23","author":"Carrero","year":"2010","journal-title":"Semin Dial"},{"key":"2026012113063080000_ehf215051-bib-0021","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.812572","article-title":"Inflammatory cytokines, immune cells, and organ interactions in heart failure","volume":"12","author":"Li","year":"2021","journal-title":"Front Physiol"},{"key":"2026012113063080000_ehf215051-bib-0022","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1161\/CIRCULATIONAHA.107.759191","article-title":"Tumor necrosis factor-\u03b1 and mortality in heart failure: A community study","volume":"118","author":"Dunlay","year":"2008","journal-title":"Circulation"},{"key":"2026012113063080000_ehf215051-bib-0023","doi-asserted-by":"publisher","first-page":"H1462","DOI":"10.1152\/ajpheart.00442.2009","article-title":"TNF-\u03b1 inhibition attenuates adverse myocardial remodeling in a rat model of volume overload","volume":"297","author":"Jobe","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026012113063080000_ehf215051-bib-0024","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-\u03b1, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"2026012113063080000_ehf215051-bib-0025","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"2026012113063080000_ehf215051-bib-0026","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10741-013-9393-8","article-title":"Could interferon-gamma be a therapeutic target for treating heart failure?","volume":"19","author":"Levick","year":"2014","journal-title":"Heart Fail Rev"},{"key":"2026012113063080000_ehf215051-bib-0027","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008145","article-title":"Protective roles of interferon-\u03b3 in cardiac hypertrophy induced by sustained pressure overload","volume":"7","author":"Kimura","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026012113063080000_ehf215051-bib-0028","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ehf2.12623","article-title":"Association of soluble interleukin-2 receptor \u03b1 and tumour necrosis factor receptor 1 with heart failure: The Multi-Ethnic Study of Atherosclerosis","volume":"7","author":"Bakhshi","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012113063080000_ehf215051-bib-0029","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1378\/chest.124.1.186","article-title":"Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: A clinical evaluation","volume":"124","author":"Grutters","year":"2003","journal-title":"Chest"},{"key":"2026012113063080000_ehf215051-bib-0030","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1084\/jem.20161791","article-title":"Th1 effector T cells selectively orchestrate cardiac fibrosis in nonischemic heart failure","volume":"214","author":"Nevers","year":"2017","journal-title":"J Exp Med"},{"key":"2026012113063080000_ehf215051-bib-0031","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/CIRCHEARTFAILURE.115.002225","article-title":"Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure","volume":"8","author":"Nevers","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026012113063080000_ehf215051-bib-0032","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cytogfr.2022.06.004","article-title":"The IL-2A receptor pathway and its role in lymphocyte differentiation and function","volume":"67","author":"Li","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"2026012113063080000_ehf215051-bib-0033","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in heart failure: JACC state-of-the-art review","volume":"75","author":"Murphy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026012113063080000_ehf215051-bib-0034","doi-asserted-by":"publisher","DOI":"10.1177\/2050312120965752","article-title":"Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer","volume":"8","author":"Amin","year":"2020","journal-title":"SAGE Open Med"},{"key":"2026012113063080000_ehf215051-bib-0035","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1161\/01.RES.81.4.627","article-title":"Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-\u03b1","volume":"81","author":"Kubota","year":"1997","journal-title":"Circ Res"},{"key":"2026012113063080000_ehf215051-bib-0036","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000350952","article-title":"Pulmonary hypertension and right heart failure in chronic kidney disease: New challenge for 21st-century cardionephrologists","volume":"3","author":"Di Lullo","year":"2013","journal-title":"Cardiorenal Med"},{"key":"2026012113063080000_ehf215051-bib-0037","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000444129","article-title":"Clinical and echocardiographic factors associated with right ventricular systolic dysfunction in hemodialysis patients","volume":"6","author":"Lopez-Quijano","year":"2016","journal-title":"Cardiorenal Med"},{"key":"2026012113063080000_ehf215051-bib-0038","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2353334","article-title":"Factors associated with risk analysis for asymptomatic left ventricular diastolic dysfunction in nondialysis patients with chronic kidney disease","volume":"46","author":"Gao","year":"2024","journal-title":"Ren Fail"},{"key":"2026012113063080000_ehf215051-bib-0039","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012113063080000_ehf215051-bib-0040","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1183\/09031936.00095606","article-title":"NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension","volume":"29","author":"Blyth","year":"2007","journal-title":"Eur Respir J"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/1\/118\/64513303\/eschf_12_1_118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/1\/118\/64513303\/eschf_12_1_118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:06:39Z","timestamp":1769018799000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/1\/118\/8261836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,9,12]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15051","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"2023-10-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}